Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobeNewsWire · Sep 30, 2026
Silexion Therapeutics Announces Exercise of WarrantsGlobeNewsWire · Sep 29, 2026
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven CancersGlobeNewsWire · Sep 28, 2026
Silexion Therapeutics to Participate in September 2026 Industry and Investor ConferencesGlobeNewsWire · Sep 9, 2026
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026
Silexion Therapeutics Announces Pricing of $2.5 Million Public OfferingGlobeNewsWire · Aug 11, 2026Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$21.20 | -$5.17 | Beat |
| May 12, 2026 | -$12.90 | -$8.50 | Beat |
| Mar 17, 2026 | -$1.17 | -$23.85 | Miss |
| Nov 12, 2025 | -$34.00 | -$28.80 | Beat |
| Aug 12, 2025 | -$31.50 | -$43.20 | Miss |
| May 13, 2025 | -$33.00 | -$38.98 | Miss |